- Qure.ai will be a global distributor for MammoScreen®, Therapixel’s AI-powered decision support tool for breast cancer screening.
- MammoScreen enables radiologists to read large numbers of screening mammograms in 2D and 3D more confidently, improving breast cancer detection accuracy and efficiency.
Back
Qure.ai, a leading medical Artificial Intelligence (AI) imaging company, announced a new partnership with Therapixel, a French firm that uses AI to improve the early breast cancer detection. Qure.ai will be a global distributor for Therapixel’s MammoScreen®.
Breast cancer is one of the most common cancers affecting women worldwide, and early detection is key to successful treatment and cure in over 90% of cases. Early detection relies on population-wide screening programs that require radiologists to read a large number of mammography exams to find around 7 cancers for 1,000 screenings. With MammoScreen®, both less experienced and expert radiologists can achieve a high detection rate and improve their reading time. Through this partnership, Qure.ai and Therapixel aim to improve the accuracy and efficiency of breast cancer detection, ultimately leading to better patient outcomes. Qure.ai now offers one of the most comprehensive imaging AI portfolios globally, covering lung and breast cancer, among other disease areas. The portfolio now covers abnormality detection across Chest X-rays, Chest CTs, Head CTs, Musculoskeletal X-rays, and Breast Mammograms. These cutting-edge AI solutions assist radiologists in faster and earlier diagnosis across different healthcare workflows and geographies.
“Qure.ai is breaking new ground by bringing a fellow radiology AI provider on board for the first time in our history. So, partnering with Therapixel is a significant milestone in Qure’s overall partnership strategy and will further complement our extensive solutions portfolio”, said Prashant Warier, CEO and Co-Founder of Qure.ai. “This collaboration also builds on Qure’s global deep distribution networks and opens a pipeline for future partnerships to strengthen our standing as a leader amongst Radiology AI platforms,” he added.
Matthieu Leclerc-Chalvet, CEO of Therapixel, added, “We are excited to partner with Qure.ai and expand the reach of MammoScreen® across the globe,” said Matthieu Leclerc-Chalvet, CEO of Therapixel. “Qure.ai’s extensive distribution network will enable us to deliver our innovative mammography solution to healthcare providers worldwide, enabling early detection of breast cancer and improved patient outcomes.”
According to recent studies, MammoScreen® enabled radiologists of all experience levels to significantly improve their performance regarding the number of cancers detected and reading time. As a result, the partnership between Qure.ai and Therapixel will benefit healthcare providers and patients globally with more accurate and efficient detection of breast cancer, ultimately leading to earlier diagnosis and better outcomes.
Channel Partner: Therapixel
